08:20 AM EDT, 09/18/2024 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Wednesday that the US Food and Drug Administration authorized an expanded access policy allowing metastatic breast cancer patients to access the company's Bria-IMT regimen beyond the scope of an ongoing pivotal phase 3 trial.

The FDA requires BriaCell to have an EAP as a condition to granting its fast track designation, the company said.

Shares of the company were up more than 7% in recent Wednesday premarket activity.

Price: 0.5034, Change: +0.03, Percent Change: +7.11